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Introduction
Oral squamous cell carcinoma (OSCC) is one of the
leading cancers worldwide and is becoming a great
health threat in Taiwan.1 Although advanced surgical
techniques and new anticancer drugs are developed
constantly, the overall postoperative survival of OSCC
patients has not improved much, with a low 5-year
survival rate of 25–30%. The overall poor prognosis
of OSCC patients is highly related to the advanced
stages (II & IV) of cancers comprising 50% of fresh
OSCC cases in medical centers. This highlights the
importance of early detection and early treatment of
oral precancerous lesions and OSCC. Yet, unlike many
other cancers such as colorectal carcinoma, hepatocel-
lular carcinoma, and prostate carcinoma, which possess
specific molecular markers useful for detection, one of
the pivotal tasks is to find useful markers for distin-
guishing cancer or precancerous lesions from normal
oral mucosa.2–6
Since OSCC exhibits aggressive biologic behavior,
the development of new treatment modalities for the
primary tumor, as well as for metastatic lesions, remains
a challenge.1–7 Previous studies of cancer biology have
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revealed that the activation of oncogenes plays an
important role in the development and progression of
malignancies. Her2/neu (also know as c-erbB-2) is 
a proto-oncogene located on human chromosome 17
and encodes a 185-kD transmembrane glycoprotein
with tyrosine kinase activity. This glycoprotein demon-
strates extensive homology to the epidermal growth
factor receptor (EGFR).8–11 Amplification of Her2/neu
oncogene or overexpression of its protein has been
demonstrated in several malignant neoplasms.7,12–18
Yet, diverse results regarding the overexpression of
Her2/neu in OSCC have been reported.19–25 This
highlights the importance of further examining the
role of Her2/neu in Taiwan, where high prevalence
of areca-related OSCC stands as the fourth highest
incidence of malignancies in males.1–3 In this study,
we investigated the expression of Her2/neu in human
tissues by the immunohistochemistry (IHC) method
in order to primarily explore its potential role in the
malignant transformation of OSCC.
Methods
Samples
All specimens were harvested from patients being
treated in Taipei Veterans General Hospital (TVGH).
This project was approved by the institutional review
board of TVGH, with informed consent signed by
patients. Specimens were collected between January
2002 and January 2005. All samples were fixed and
sectioned following standard protocols.2,6 The samples
included 20 normal oral mucosa (NOM) lesions, 20
epithelial dysplasia (ED) lesions and 30 pathologically
proven OSCCs, which had undergone wide excision
of the primary lesions. The mean ages of the 3 groups
(NOM, ED, OSCC) were 46 ± 7 years, 51 ± 6 years,
and 53 ± 9 years, respectively. The gender ratios of
male/female were 7:3, 13:7, and 22:8, respectively.
The clinicopathologic features, including areca use,
tumor size, neck lymph node (LN) metastasis, differ-
entiation, and stages of OSCC subjects, were recorded.
IHC
Sections were deparaffinized in xylene and rehydrated
by immersion in a graded series of ethanol dilutions.
All slides were immersed in 10 mm sodium citrate
solution, in a microwave oven, to retrieve antigenicity.
Sections were quenched with 3% fresh H2O2 for 10
minutes to inhibit endogenous tissue peroxidase
activity, and rinsed with 1 × PBS for 5 minutes twice.
Sections were further incubated in blocking serum for
30 minutes and then 2.5 hours with primary Neu
(ICR12) sc-57378 rat monoclonal IgG2a antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) in
a humid chamber. After washing with 1 × PBS for 
5 minutes twice, sections were then incubated with
biotinylated secondary antibody solution for 30 min-
utes. LSAB2® streptavidin-peroxidase detection reagent
(DAKO, Santa Barbara, CA, USA) was subsequently
added evenly over the sections and incubated for 
30 minutes. The sections were washed with 1 × PBS
for 5 minutes twice, incubated with freshly prepared
aminoethylcarbazole (AEC; Zymed, South San
Francisco, CA, USA) substrate solution for 15 minutes
and then washed with 1 × PBS. All IHC staining was
performed at room temperature. The sections were
finally counterstained with hematoxylin, washed with
1 × PBS and de-ionized distilled water, and then
mounted. The percentage of immunoreactive cells were
estimated in 5 random 400 microscopic fields.2 The
tissue sections were categorized as Her2/neu(++),
Her2/neu(+) or Her2/neu(−) when over 50%,
10–50%, or < 10% of cells were positive for immuno-
staining, respectively.
Statistical analysis
The significance of Her2/neu immunoreactivity in
different groups or with different covariates was
investigated using Fisher’s exact test. A p value of less
than 0.05 was considered to be statistically significant.
Results
Characteristics of cases
The mean age of the 30 OSCC cases was 52 ± 7 years
(range, 36–69 years). A marked gender difference
between males and females (25 vs. 5) was consistent
with a previous report on OSCC in Taiwan.1 The
mean ages of the NOM and OPL groups were 47 ± 7
years and 50 ± 9 years, respectively, showing no signif-
icant difference in age among the different groups.
The tissue samples of the NOM and ED groups were
mainly from buccal mucosa. The tissue samples of
OSCC were harvested from buccal mucosa (13 cases),
tongue (5 cases), gingiva (5 cases), mouth floor (6 cases)
and palate (1 case). The immunoreactivity in OSCC
cases was analyzed. Twenty-four (24/30, 80%) cases
were areca users and 6 (6/30, 20%) were non-users.
Twelve cases (12/30, 40%) had an extensive T4 tumor
mass. Eighteen (18/30, 60%) had tumor size ranging
from T1 to T3. Twenty-two (22/30, 73%) cases were
neck node negative. Eight (8/30, 27%) had neck nodal
metastasis. Eighteen (18/30, 60%) were well differen-
tiated OSCCs. Twelve (12/30, 40%) were moderately
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differentiated to poorly differentiated OSCCs. Stage IV
tumors were present in 14 (14/30, 47%) cases. Stage
I–III tumors were present in 16 (16/30, 53%) cases
(Table 1).
Her2/neu immunoreactivity
Her2/neu immunoreactivity was scarcely observed in
the membranous or cytosolic compartments of NOMs
and in the majority of EDs. Her2/neu immunoreac-
tivity was scored according to the number of cells
exhibiting immunostaining. All except 2 NOM cases
exhibited Her2/neu(–) (Figure 1A). Her2/neu(+)
and (++) only appeared in 5 (5/20, 25%) ED cases
(Figure 1B). In contrast, 12 (12/30, 40%) OSCCs
were Her2/neu(+) and another 3 (3/30, 10%) OSCCs
were (++) (Figures 1C and 1D). The remaining 15
OSCCs showed scattered Neu immunoreactivity and
were scored as Her2/neu(–). Significant difference in
Neu immunoreactivity was noted between ED and
OSCC groups (p < 0.05, Fisher’s exact test; Figure 2).
While most clinical features of OSCC including areca
use, tumor size, neck LN metastasis, and differentiation
showed no correlation to Neu gene expression by IHC
examination, tumor stage was noted to have significant
correlation to Neu expression. In all, no significant
difference in Neu differential expression was associated
with clinicopathologic covariates (Table 1).
Discussion
In our study, Her2/neu expression in NOM was almost
undetectable and very low in ED. Significantly higher
Her2/neu expression in the OSCC group than the
NOM and ED groups was also noted. Furthermore,
Her2/neu expression was significantly higher in the
advanced stage IV cases than the stage I–III cases.
This implied that the aberrant expression of Her2/neu
could play a potential role in the progression of
malignant transformation of OSCC instead of the early
promotion stages. In the OSCC group, purely tumor
size, neck nodal metastasis or differentiation did not
have a statistically unique result as staging of the tumor
in correlation to Her2/neu expression. Whether this
was due to the sample size or its role in the transfor-
mation being irrelevant to the above covariates needs
further exploration. Obviously, the overexpression of
Her2/neu could be a potential useful marker in dis-
tinguishing non-cancer and cancer, as shown in this
study. Once the overexpression of Her2/neu is found
in cases with benign or precancerous lesions in the oral
cavity, care should be taken in the follow-up of such
patients. Early treatment with excision of the ED
showing expression of Her2/neu may be required.
An attractive target for receptor-mediated immunother-
apy has been conducted in several large clinical multi-
center trials as first-line therapy for metastatic breast
carcinomas that exhibited Her2/neu overexpression.
In this clinical trial, trastuzumab (Herceptin; Genentech,
San Francisco, CA, USA), a humanized monoclonal
antibody directed against the extracellular domain of
the Her2/neu protein, was studied.15–17 Whether
Her2/neu could be treated as a molecular target for
anticancer therapy in OSCC exhibiting overexpression
of Her2/neu remains unknown and certainly warrants
attention and value as an approach for clinical trials.
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Table 1. Analysis of the association of clinicopathologic covariates with Her2/neu expression in oral squamous cell carcinoma
Her2/neu(−) Her2/neu(+) p*
Areca use 0.35
User (n = 24) 12 12
Non-user (n = 6) 3 3
Size 0.36
T1–T3 (n = 18) 10 8
T4 (n = 12) 5 7
Lymph node 0.34
N = 0 (n = 22) 12 10
N > 0 (n = 8) 3 5
Differentiation 0.36
Well differentiated (n = 18) 10 8
Moderately & poorly differentiated (n = 12) 5 7
Stage 0.14
I–III (n = 16) 10 6
IV (n = 14) 5 9
Alterations of the Her2/neu proto-oncogene have
been implicated in the carcinogenesis and prognosis
of many cancers, especially breast cacner.7,12–18 Its
overexpression is correlated with a poor prognosis for
breast and ovarian cancer patients. Aberrant expression
of Her2/neu has been frequently observed in OSCC,
but the reported results are controversial because of
their wide range (between 0% and 88%).7,19–25 The
lack of a unique marker of OSCC has long been 
a problem in the early detection of OSCC. It would
be necessary to discover more reliable and efficient
markers to characterize the malignant transformation
of oral epithelia.1–4 Thus, the aim of this study was
primarily to examine the expression of Her2/neu in
the human tissues of NOM, ED and OSCC cases to
validate the controversial results of various studies and
to determine whether Her2/neu could be considered
as a useful marker for oral cancer.
Her2/neu overexpression was seen in many cancers,
but was controversial in OSCC from different reports.
J Chin Med Assoc • March 2008 • Vol 71 • No 3126
Y. Fong, et al
A B
DC
Figure 1. Her2/neu immunoreactivity in normal oral mucosa (NOM), epithelial dysplasia (ED) and oral squamous cell carcinoma
(OSCC). Immunohistochemistry (IHC) showed differential expression between NOM/ED and OSCC. (A) NOM (Her2/neu(−), 100×). 
(B) Black arrows indicate the area of ED (Her2/neu(−), 400×). (C) Weak positive staining in most area of OSCC (Her2/neu(+), 100×). 
(D) Black arrows indicate some strong focal cytoplasmic staining in OSCC (Her2/neu(++), 400×).
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Figure 2. Elevated Her2/neu expression in stepwise carcinogene-
sis. Significant difference in Neu immunoreactivity was noted
between the epithelial dysplasia (ED) and oral squamous cell car-
cinoma (OSCC) groups. NOM = normal oral mucosa.
We investigated its association of expression in oral
carcinogenesis by IHC. Significant difference was
observed between NOM/ED and OSCC cases.
Significant increase of expression from stages I to III
to the advanced stage IV OSCC cases was observed.
Her2/neu can potentially be a useful marker in dis-
tinguishing NOM/ED from OSCC.
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